Discussion on development of four diagnostic information scale for clinical re-evaluation of postmarketing herbs.
- Author:
Wei HE
1
;
Yanming XIE
;
Yongyan WANG
Author Information
1. Post-Doctoral Station of China Academy of Chinese Medical Sciences, Beijing 100700, China. hewei7826@163.com
- Publication Type:Journal Article
- MeSH:
Clinical Trials as Topic;
Humans;
Medicine, Chinese Traditional;
adverse effects;
Product Surveillance, Postmarketing;
Research Design
- From:
China Journal of Chinese Materia Medica
2011;36(24):3548-3550
- CountryChina
- Language:Chinese
-
Abstract:
Post-marketing re-evaluation of Chinese herbs can well reflect Chinese medicine characteristics, which is the most easily overlooked the clinical re-evaluation content. Since little attention has been paid to this, study on the clinical trial design method was lost. It is difficult to improving the effectiveness and safety of traditional Chinese medicine. Therefore, more attention should be paid on re-evaluation of the clinical trial design method point about tcm syndrome such as the type of research program design, the study of Chinese medical information collection scale and statistical analysis methods, so as to improve the clinical trial design method study about tcm syndrome of Chinese herbs postmarketing re-evalutation status.
